Pular para o conteúdo
Miastenia gravis
ORPHA:589CID-10 · G70.0CID-11 · 8C60OMIM 254200DOENÇA RARA
Esta doença tem causa genética. Recomendamos procurar um médico geneticista para diagnóstico, exames genéticos e aconselhamento familiar.
MuscularInício todas idadesHerança Complex/Unknown
Também conhecida comoMiasteniaMiastenia GraveMG

A miastenia gravis (MG) é uma doença autoimune rara, clinicamente heterogênea e da junção neuromuscular, caracterizada por fraqueza cansativa dos músculos voluntários.

Última verificação: Fonte: não verificado (3 pendências)Em construçãohistóricoSugerir correção
Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

💬
EM LINGUAGEM SIMPLES

Miastenia gravis é uma condição que causa fraqueza dos músculos esqueléticos, que são os músculos que o corpo usa para o movimento. A fraqueza geralmente começa nos músculos ao redor dos olhos, causando queda das pálpebras (ptose) e dificuldade em coordenar os movimentos oculares, o que resulta em visão embaçada ou dupla. Em uma forma da condição chamada miastenia ocular, a fraqueza permanece confinada aos músculos dos olhos. Na maioria das pessoas com miastenia gravis, porém, músculos adicionais no rosto e no pescoço são afetados. As pessoas com a condição podem apresentar expressões faciais incomuns, dificuldade em manter a cabeça erguida, comprometimento da fala (disartria) e problemas de mastigação e deglutição (disfagia) que podem levar a engasgos, atragamentos ou baba.

Outros músculos do corpo também são afetados em algumas pessoas com miastenia gravis. Os músculos dos braços e das pernas podem estar envolvidos, fazendo com que as pessoas com a condição apresentem alterações na marcha ou dificuldade ao levantar objetos, ao levantar‑se de uma posição sentada ou ao subir escadas. A fraqueza muscular tende a flutuar ao longo do tempo; normalmente piora com a atividade e melhora com o repouso.

A fraqueza dos músculos da parede torácica e do músculo que separa o abdômen da cavidade torácica (o diafragma) pode causar problemas respiratórios em algumas pessoas com miastenia gravis. Cerca de 10 por cento das pessoas com essa condição experimentam uma complicação potencialmente fatal na qual esses músculos respiratórios enfraquecem a ponto de a respiração ficar perigosamente comprometida, e a pessoa afetada necessita de assistência ventilatória. Essa insuficiência respiratória, chamada crise miastênica, pode ser desencadeada por estresses como infecções ou reações a medicamentos.

Pessoas podem desenvolver miastenia gravis em qualquer idade. Por razões desconhecidas, ela é mais frequentemente diagnosticada em mulheres com menos de 40 anos e em homens com mais de 60 anos. É incomum em crianças, mas alguns bebês nascidos de mulheres com miastenia gravis apresentam sinais e sintomas da condição nos primeiros dias ou semanas de vida. Essa ocorrência temporária de sintomas é chamada de miastenia gravis neonatal transitória.

Fonte: MedlinePlus Genetics (NLM/NIH), traduzido
📋
Informacoes curadas por IA — podem conter imprecisoes

A miastenia gravis (MG) é uma doença autoimune rara, clinicamente heterogênea e da junção neuromuscular, caracterizada por fraqueza cansativa dos músculos voluntários.

Pesquisas ativas
153 ensaios
326 total registrados no ClinicalTrials.gov
Publicações científicas
19.273 artigos
Último publicado: 2026 Mar
Medicamentos
6 com registro
Piridostigmina, Azatioprina, Eculizumabe

Tem tratamento?

✓ 6 medicamentos específicos desta doença (registro ANVISA, FDA ou SUS/CEAF)
Ver detalhes, fases e interações →
PIRIDOSTIGMINAAZATIOPRINAECULIZUMABEMESTINONBKEMV (ECULIZUMAB-AEEB)PYRIDOSTIGMINE BROMIDE (PYRIDOSTIGMINE BROMIDE)

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
1-9 / 100 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
20.0
Europe
Início
All ages
🏥
SUS: Cobertura parcialScore: 65%
3 medicamentos CEAF2 procedimentos SIGTAPCID-10: G70.0
🇧🇷Dados SUS / DATASUS
EXAMES E PROCEDIMENTOS RELACIONADOS (2)
•
Sequenciamento completo do exoma (WES)
•
Atendimento em reabilitação — doenças raras
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

💪
Músculos
9 sintomas
🧠
Neurológico
4 sintomas
📏
Crescimento
3 sintomas
😀
Face
2 sintomas
🛡️
Imunológico
2 sintomas
🫁
Pulmão
2 sintomas

+ 33 sintomas em outras categorias

Características mais comuns

90%prev.
Fraqueza muscular
Muito frequente (99-80%)
55%prev.
Positividade do anticorpo anti-titina
Frequente (79-30%)
55%prev.
Fraqueza muscular de membro
Frequente (79-30%)
55%prev.
Diplopia
Frequente (79-30%)
55%prev.
Fraqueza fatigável dos músculos esqueléticos
Frequente (79-30%)
55%prev.
Dificuldade para subir escadas
Frequente (79-30%)
62sintomas
Muito frequente (1)
Frequente (24)
Ocasional (14)
Muito raro (6)
Sem dados (17)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 62 características clínicas mais associadas, ordenadas por frequência.

Fraqueza muscularMuscle weakness
Muito frequente (99-80%)90%
Positividade do anticorpo anti-titinaAnti-titin antibody positivity
Frequente (79-30%)55%
Fraqueza muscular de membroLimb muscle weakness
Frequente (79-30%)55%
Frequente (79-30%)55%
Fraqueza fatigável dos músculos esqueléticosFatigable weakness of skeletal muscles
Frequente (79-30%)55%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico19.273PubMed
Últimos 10 anos200publicações
Pico2026191 papers
Linha do tempo
2026Hoje · 2026🧪 1993Primeiro ensaio clínico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

3 genes identificados com associação a esta condição. Padrão de herança: Multigenic/multifactorial, Not applicable.

HLA-DQA1HLA class II histocompatibility antigen, DQ alpha 1 chainCandidate gene tested inTolerante
VIAS BIOLÓGICAS (7)
Generation of second messenger moleculesTranslocation of ZAP-70 to Immunological synapsePhosphorylation of CD3 and TCR zeta chainsCo-inhibition by PD-1Downstream TCR signaling
EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
456.0 TPM
Pulmão
91.4 TPM
Baço
90.3 TPM
Tecido adiposo
34.6 TPM
Nervo tibial
30.4 TPM
OUTRAS DOENÇAS (3)
adult-onset myasthenia gravisidiopathic achalasiaceliac disease, susceptibility to, 1
HGNC:4942UniProt:P01909
CTLA4Cytotoxic T-lymphocyte protein 4Candidate gene tested inAltamente restrito
VIAS BIOLÓGICAS (3)
Co-stimulation by CD28Co-inhibition by CTLA4RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs)
MECANISMO DE DOENÇA

Systemic lupus erythematosus

A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.

EXPRESSÃO TECIDUAL(Tecido-específico)
Baço
5.8 TPM
Intestino delgado
4.9 TPM
Pulmão
4.3 TPM
Testículo
2.5 TPM
Sangue
1.8 TPM
OUTRAS DOENÇAS (6)
autoimmune lymphoproliferative syndrome due to CTLA4 haploinsufficiencysystemic lupus erythematosusgranulomatosis with polyangiitismycosis fungoides
HGNC:2505UniProt:P16410
TNFRSF11ATumor necrosis factor receptor superfamily member 11ACandidate gene tested inTolerante
VIAS BIOLÓGICAS (2)
TNFR2 non-canonical NF-kB pathwayTNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway
MECANISMO DE DOENÇA

Familial expansile osteolysis

Rare autosomal dominant bone disorder characterized by focal areas of increased bone remodeling. The osteolytic lesions develop usually in the long bones during early adulthood. FEO is often associated with early-onset deafness and loss of dentition.

EXPRESSÃO TECIDUAL(Tecido-específico)
Glândula salivar
10.6 TPM
Pituitária
9.9 TPM
Cólon transverso
8.4 TPM
Intestino delgado
7.9 TPM
Skin Sun Exposed Lower leg
2.8 TPM
OUTRAS DOENÇAS (6)
familial expansile osteolysisautosomal recessive osteopetrosis 7adult-onset myasthenia gravisdysosteosclerosis
HGNC:11908UniProt:Q9Y6Q6

Medicamentos aprovados (FDA)

2 medicamentos encontrados nos registros da FDA americana.

💊 BKEMV (ECULIZUMAB-AEEB)
💊 Pyridostigmine Bromide (PYRIDOSTIGMINE BROMIDE)
Ver no DailyMed/FDA

Variantes genéticas (ClinVar)

263 variantes patogênicas registradas no ClinVar.

🧬 HLA-DQA1: NM_002122.5(HLA-DQA1):c.249G>A (p.Gln83=) ()
🧬 HLA-DQA1: GRCh37/hg19 6p21.33-21.31(chr6:31036397-34088832)x3 ()
🧬 HLA-DQA1: GRCh37/hg19 6p22.1-q14.1(chr6:29455465-81447367) ()
🧬 HLA-DQA1: GRCh37/hg19 6p25.3-q27(chr6:156975-170919482) ()
🧬 HLA-DQA1: GRCh37/hg19 6p25.3-q27(chr6:156975-170919482)x3 ()
Ver todas no ClinVar

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
✓Aprovado5
3Fase 323
2Fase 212
1Fase 114
·Pré-clínico46
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 100 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Miastenia gravis

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

Onde estão os ensaios

Com ensaio aberto em 35 países. O ponto verde marca onde há vaga agora.

🟢 Recrutando agora

98 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

NCT06987539 · A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, …Recrutando
PHASE2🇧🇷 Brasil · 🇦🇷 Argentina · 🇫🇷 França +5
NCT06607627 · PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatr…Recrutando
PHASE3🇧🇷 Brasil · 🇯🇵 Japão · 🇵🇱 Polônia +2
NCT06193889 · KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cel…Recrutando
PHASE2, PHASE3🇧🇷 Brasil · 🇦🇺 Austrália · 🇩🇪 Alemanha +3
NCT06456580 · A Study of Telitacicept for the Treatment of Generalized Mya…Recrutando
PHASE3🇧🇷 Brasil · 🇦🇷 Argentina · 🇦🇺 Austrália +11
NCT07673744 · A Study to Evaluate the Efficacy and Safety of Maintenance U…Recrutando
PHASE2🇺🇸 Estados Unidos
NCT07465289 · A Study to Evaluate The Long-Term Safety And Efficacy of Roz…Recrutando
PHASE3🇨🇳 China · 🇯🇵 Japão · 🇪🇸 Espanha +1
NCT07787247 · Feasibility of Remote Monitoring of Patients With Myasthenia…Recrutando
🇺🇸 Estados Unidos
NCT07596784 · Efficacy and Safety of Ravulizumab in Chinese Adults Partici…Recrutando
PHASE3🇨🇳 China
NCT07673627 · ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tol…Recrutando
PHASE2🇺🇸 Estados Unidos
NCT07647510 · A Phase 3 Study to Evaluate Claseprubart in Adults With Gene…Recrutando
PHASE3🇺🇸 Estados Unidos
NCT07570589 · Monitor the Evolution of Myasthenia Gravis Symptoms in Real-…Recrutando
🇫🇷 França
NCT07717281 · PANORAMA: Neuromuscular Organoids for Refractory AChR+ Myast…Recrutando
🇮🇹 Itália
NCT07463521 · A Study to Evaluate the Efficacy and Safety of Rozanolixizum…Recrutando
PHASE3🇨🇦 Canadá · 🇨🇳 China · 🇯🇵 Japão +2
NCT07501702 · A Phase 2 Study to Evaluate Povetacicept in Adults With Gene…Recrutando
PHASE2🇦🇺 Austrália · 🇵🇱 Polônia · Turkey (Türkiye) +2
NCT07596901 · Study of Aritinercept in Patients With Generalized Myastheni…Recrutando
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT07304154 · A Study Evaluating the Safety and Efficacy of KITE-363 in Re…Recrutando
PHASE1🇦🇺 Austrália · 🇨🇦 Canadá · 🇺🇸 Estados Unidos
NCT06866652 · Evaluating Dyspnea in Autoimmune Myasthenia Gravis "Why am I…Recrutando
🇫🇷 França
NCT07526493 · Safety and Pharmacodynamics of QH103 Cell Injection in the T…Recrutando
PHASE1🇨🇳 China
NCT07761026 · AXIS MG Patient RegistryRecrutando
🇺🇸 Estados Unidos
NCT07413835 · Efficacy and Safety of HN2302 in Refractory Myasthenia Gravi…Recrutando
NA🇨🇳 China
NCT07470151 · Clinical Study of EVM18001 in the Treatment of Refractory Au…Recrutando
NA🇨🇳 China
NCT07478172 · Effects of Whole-body Electrical Muscle Stimulation Exercise…Recrutando
NA🇺🇸 Estados Unidos
NCT07221838 · A Study to Investigate OCS Tapering in Adult Participants Wi…Recrutando
PHASE4🇩🇪 Alemanha · 🇮🇹 Itália · 🇯🇵 Japão +1
NCT07595653 · A Study to Evaluate the Impact of Efgartigimod on Overall Di…Recrutando
🇮🇹 Itália
NCT07250750 · A Phase 1b/2 Study of IM-101 in Adult Participants With Gene…Recrutando
PHASE1, PHASE2Bulgaria · 🇮🇹 Itália · 🇵🇱 Polônia +3
NCT07215949 · Zilucoplan for Severe gMG ExacerbationsRecrutando
PHASE3🇺🇸 Estados Unidos
NCT07089121 · Descartes-08 for Children, Adolescents, and Young Adults Wit…Recrutando
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT07249632 · A Study of Telitacicept in Patients With Ocular Myasthenia G…Recrutando
PHASE3🇨🇳 China
NCT07217587 · Comparative Efficacy of Nipocalimab and Efgartigimod in Part…Recrutando
PHASE3🇮🇱 Israel · 🇨🇭 Suíça · 🇺🇸 Estados Unidos
NCT07247279 · Epidemiological Study of Treatment Approaches in AChR-Antibo…Recrutando
Russia
NCT07294170 · ADAPT Forward - Master Protocol of a Platform Study to Evalu…Recrutando
🇧🇪 Bélgica · 🇩🇪 Alemanha · Greece +5
NCT07284420 · ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart I…Recrutando
PHASE2🇧🇪 Bélgica · 🇩🇪 Alemanha · Greece +5
NCT07337785 · CD19/BCMA-Targeted UCAR-T for Patients With Neurological Aut…Recrutando
EARLY_PHASE1🇨🇳 China
NCT07246564 · Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizu…Recrutando
PHASE4🇨🇳 China
NCT07411963 · Evaluation of the Condition of Patients Receiving EARLY Ravu…Recrutando
🇫🇷 França
NCT07072988 · Evaluate the Benefit of Corticoid Sparing in Elderly With Ge…Recrutando
PHASE4🇫🇷 França
NCT07215650 · Clinical Study of Cizutamig in Generalized Myasthenia Gravis…Recrutando
PHASE1🇨🇳 China
NCT06967480 · Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive …Recrutando
🇮🇹 Itália
NCT07058298 · GC012F Injection in the Treatment of Refractory Generalized …Recrutando
EARLY_PHASE1🇨🇳 China
NCT06939166 · Universal Chimeric Antigen Receptor T-Cell (UCAR T-cell) The…Recrutando
EARLY_PHASE1🇨🇳 China
NCT07039916 · Study to Assess the Efficacy and Safety of IMVT-1402 in Part…Recrutando
PHASE3🇦🇷 Argentina · 🇨🇿 Tchéquia · 🇩🇰 Dinamarca +12
NCT06909253 · Ravulizumab Treatment Outcomes in Patients With Generalized …Recrutando
🇵🇱 Polônia
NCT06680037 · A Study to Assess the Safety and Clinical Activity of Azer-c…Recrutando
PHASE1🇺🇸 Estados Unidos
NCT06626919 · A Phase 1 Study of Anitocabtagene Autoleucel for the Treatme…Recrutando
PHASE1🇺🇸 Estados Unidos
NCT06342544 · Immediate Corticosteroid Therapy and Rituximab to Prevent Ge…Recrutando
PHASE3🇫🇷 França
NCT06909214 · A Study to Evaluate the Clinical Outcomes of Efgartigimod PH…Recrutando
PHASE4🇺🇸 Estados Unidos
NCT07022197 · Safety and Efficacy of BAFF-R CART for Refractory Neuroimmun…Recrutando
PHASE1, PHASE2🇨🇳 China
NCT06743490 · Capturing Key MG-symptoms Using Smartphone Recordings.Recrutando
🇳🇱 Países Baixos
NCT06860633 · Treatment of Myasthenia Gravis Exacerbation or Crisis With E…Recrutando
PHASE4🇺🇸 Estados Unidos
NCT06688435 · A Study to Evaluate the Safety and Preliminary Efficacy of S…Recrutando
PHASE1🇨🇳 China
NCT06815133 · Effectiveness and Safety of Zilucoplan Treatment for French …Recrutando
🇫🇷 França
NCT06866483 · Validation and Scaling of Screening Program for Undiagnosed …Recrutando
🇺🇸 Estados Unidos
NCT06765161 · Efgartigimod in IVIG Dependent Myasthenia Gravis PatientsRecrutando
PHASE3🇨🇦 Canadá
NCT06359041 · RESET-MG: A Study to Evaluate the Safety and Efficacy of CAB…Recrutando
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT06312644 · Study of Ultomiris® (Ravulizumab) Safety in PregnancyRecrutando
🇦🇺 Austrália · 🇫🇷 França · 🇩🇪 Alemanha +4
NCT06941584 · Analysis of the Role of AIRE in Autoimmune Neurological Dise…Recrutando
🇮🇹 Itália
NCT06298565 · A Non-interventional, Post-authorisation Safety Study of Pat…Recrutando
🇦🇹 Áustria · 🇧🇪 Bélgica · 🇩🇪 Alemanha +3
NCT06055959 · A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Par…Recrutando
PHASE2, PHASE3🇮🇹 Itália · 🇵🇱 Polônia · South Korea +2
NCT06491238 · Light vs. Moderate Intensity Exercise in Individuals With My…Recrutando
NA🇺🇸 Estados Unidos
NCT07085676 · Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmu…Recrutando
PHASE1🇮🇱 Israel
NCT06502015 · Biomarkers in Autoimmune Disease of Nervous SystemRecrutando
🇨🇳 China
NCT06064461 · Vitaccess Real MG RegistryRecrutando
🇬🇧 Reino Unido · 🇺🇸 Estados Unidos
NCT06371040 · Safety and Efficacy of CD19-BCMA Targeted CAR-T Therapy for …Recrutando
PHASE1🇨🇳 China
NCT06447597 · A Clinical Study of B007 in the Treatment of Generalized Mya…Recrutando
PHASE2, PHASE3🇨🇳 China
NCT06392386 · A Study of Efgartigimod PH20 SC in Children Between 2 and Le…Recrutando
PHASE2, PHASE3🇦🇺 Austrália · 🇧🇪 Bélgica · 🇨🇦 Canadá +11
NCT06463587 · Efficacy and Safety of a New Formulation of Oral Cladribine …Recrutando
PHASE3🇦🇷 Argentina · 🇦🇺 Austrália · 🇧🇪 Bélgica +22
NCT06455709 · Markers of Favorable Response to Complement Inhibitors Thera…Recrutando
🇮🇹 Itália
NCT06414954 · Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Pati…Recrutando
PHASE2🇧🇪 Bélgica · 🇩🇰 Dinamarca · 🇫🇷 França +7
NCT07653984 · Cohort Study on Neuroimmune Diseases in the Reproductive AgeRecrutando
🇨🇳 China
NCT07136844 · Gait Analysis Parameter and Upper Limb Evaluation in Adult P…Recrutando
NA🇧🇪 Bélgica
NCT06249438 · A Study of C-CAR168 in the Treatment of Autoimmune Diseases …Recrutando
PHASE1🇨🇳 China
NCT06241521 · Myasthenia Gravis Registry in ChinaRecrutando
🇨🇳 China
NCT04535843 · Precision Diagnosis and Prospective Cohort Study for Myasthe…Recrutando
🇨🇳 China
NCT05564936 · The ME&MG Digital Solution for Autonomous Assessment of Myas…Recrutando
NA🇫🇷 França · 🇺🇸 Estados Unidos
NCT06299748 · A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal…Recrutando
🇩🇪 Alemanha · 🇮🇹 Itália · 🇪🇸 Espanha +1
NCT07146425 · Construction of A Multimodal Digital Assessment Model for My…Recrutando
🇨🇳 China
NCT06259071 · MuSK Myasthenia 1000 StudyRecrutando
🇺🇸 Estados Unidos
NCT06064695 · Effects of Whole-body Electrical Muscle Stimulation Exercise…Recrutando
NA🇺🇸 Estados Unidos
NCT06879210 · Application of Artificial Intelligence in Precision Medicine…Recrutando
NA🇹🇼 Taiwan
NCT06754020 · TCM Tongue Diagnosis and Syndrome Differentiation in Myasthe…Recrutando
NA🇹🇼 Taiwan
NCT05067348 · Efficacy and Safety of Tocilizumab in the Treatment of Gener…Recrutando
PHASE2🇨🇳 China
NCT05265273 · A Study of Nipocalimab in Children Aged 2 to Less Than 18 Ye…Recrutando
PHASE2, PHASE3🇯🇵 Japão · 🇳🇱 Países Baixos · 🇵🇱 Polônia +1
NCT05337891 · Sensitivity of Repetitive Nerve Stimulation Performed in the…Recrutando
🇵🇱 Polônia
NCT04833894 · Evaluating the Pharmacokinetics, Pharmacodynamics, and Safet…Recrutando
PHASE2, PHASE3🇦🇹 Áustria · 🇧🇪 Bélgica · 🇨🇦 Canadá +9
NCT04951622 · A Study of Nipocalimab Administered to Adults With Generaliz…Recrutando
PHASE3🇦🇺 Austrália · 🇧🇪 Bélgica · 🇨🇦 Canadá +14
NCT04561557 · Safety and Efficacy of CT103A Cells for Relapsed/Refractory …Recrutando
EARLY_PHASE1🇨🇳 China
NCT04202341 · Registry of Participants With Generalized Myasthenia Gravis …Recrutando
🇦🇹 Áustria · 🇨🇦 Canadá · 🇨🇳 China +4
NCT04182984 · TheRapeutic Effect of Different immunosuppressAnts on Non-Th…Recrutando
🇨🇳 China
NCT06940323 · Pregnancy Registry, Infants, Serum/Milk Analysis (PRISMA)Recrutando
🇺🇸 Estados Unidos
NCT03792659 · The EXPLORE MG Registry for Myasthenia GravisRecrutando
🇺🇸 Estados Unidos
NCT06617741 · Myasthenia Gravis Foundation of America Global MG Patient Re…Recrutando
🇺🇸 Estados Unidos
NCT07217509 · PPDTM CorEvitasTM Myasthenia Gravis (MG) Drug Safety and Eff…Por convite
🇺🇸 Estados Unidos
NCT06877403 · Prevalence and Impact of Fatigue in Myasthenic Patients Foll…Por convite
🇫🇷 França
NCT06435312 · An Open-label Extension Study to Evaluate Subcutaneous Ziluc…Por convite
PHASE3🇮🇹 Itália · 🇵🇱 Polônia · South Korea +1
NCT06540144 · An Extension Study Evaluating 6-week Treatment Cycles of Roz…Por convite
PHASE3🇮🇹 Itália · 🇯🇵 Japão · 🇵🇱 Polônia +2
NCT06605612 · Development and Validation of the FBIndex to Determine the R…Por convite
🇩🇪 Alemanha
NCT05374590 · Evaluating Long-term Safety of Efgartigimod Administered Int…Por convite
PHASE2, PHASE3🇧🇪 Bélgica · 🇨🇦 Canadá · 🇫🇷 França +7
NCT00704626 · Serum Auto-Antibodies in Neurological DiseasesPor convite
🇺🇸 Estados Unidos

Outros ensaios clínicos

326 ensaios clínicos encontrados, 153 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

🥈Melhor nível de evidência: Observacional
Timeline de publicações
7.291 papers (10 anos)

Mostrando amostra de 200 publicações de um total de 7.291

#1

Half a century of change: demographic trends and their clinical impact in acetylcholine receptor antibody-positive myasthenia gravis.

Journal of neurology2026 Mar 23

Este estudo de 50 anos revela uma mudança demográfica na Miastenia Gravis (MG), com a idade média de início aumentando significativamente para pacientes mais velhos. Para pacientes e médicos, é crucial saber que pacientes com início precoce tendem a ter melhores taxas de remissão completa ou mínima, enquanto aqueles com início muito tardio frequentemente enfrentam um manejo mais desafiador e maior risco de eventos adversos relacionados ao tratamento.

🇧🇷 traduzido
#2

Neuro-immune interactions underlying autoimmune diseases: insights from brain imaging data.

Molecular brain2026 Mar 19

Este estudo inovador aponta que o cérebro (Sistema Nervoso Central) tem um papel causal no desenvolvimento de doenças autoimunes, como a Miastenia Gravis, influenciando-as através de interações com o sistema imunitário. Para pacientes e médicos, esta descoberta abre caminho para o desenvolvimento de novas e promissoras estratégias de diagnóstico e tratamento, que visam modular as complexas conexões entre o cérebro e a imunidade.

🇧🇷 traduzido
#3

Morvan syndrome in a patient with progressing metastatic thymoma and myasthenia gravis.

BMJ case reports2026 Mar 19

A Síndrome de Morvan (SM) é uma condição paraneoplásica rara que pode surgir em pacientes com doenças autoimunes como a Miastenia Gravis (MG), especialmente em casos de timoma. O artigo descreve um caso em que o reconhecimento e o diagnóstico precoce da SM foram cruciais para a administração de imunoterapia oportuna. Isso levou a uma melhora clínica rápida e significativa, sublinhando a importância vital da vigilância para médicos e pacientes diante de sintomas neurológicos complexos.

🇧🇷 traduzido
#4

Risk of New-Onset Myasthenia Gravis Following COVID-19 Infection and Vaccination: A Population-Based Case-Control Study.

European journal of neurology2026 Mar

Este estudo sugere que a infecção por COVID-19 não está significativamente associada a um risco aumentado de miastenia gravis (MG) de novo início. No entanto, a vacina Pfizer-BioNTech parece estar associada a um risco maior de desenvolver MG, especialmente dentro de 180 dias após a vacinação. Este é um ponto importante para pacientes e médicos considerarem ao avaliar riscos e benefícios da vacinação e no monitoramento de novos sintomas.

🇧🇷 traduzido
#5

Minimal Symptom Expression in Generalized Myasthenia Gravis: A Valuable Patient-Centric Treatment Goal.

European journal of neurology2026 Mar

Para pacientes e médicos com miastenia gravis generalizada (gMG), a **"Expressão Mínima de Sintomas" (MSE)** surge como um objetivo de tratamento valioso e focado no paciente. A MSE, que significa ter sintomas quase inexistentes nas atividades diárias, é alcançável com terapias biológicas modernas, correlaciona-se com melhorias significativas na qualidade de vida e avaliações médicas. Ela serve como uma meta prática e integrada para o manejo da doença, priorizando o bem-estar do paciente.

🇧🇷 traduzido

Publicações recentes

Ver todas no PubMed

📚 EuropePMC13.933 artigos no totalmostrando 194

2026

Should Patients With Ocular Myasthenia Gravis Be Started on Immunosuppression to Prevent Generalization?

Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society
2026

Half a century of change: demographic trends and their clinical impact in acetylcholine receptor antibody-positive myasthenia gravis.

Journal of neurology
2026

On the increased prevalence of myasthenia gravis in patients with inflammatory bowel disease.

Arquivos de neuro-psiquiatria
2026

Beyond numbers: challenges in assessing myasthenia gravis prevalence in inflammatory bowel disease.

Arquivos de neuro-psiquiatria
2026

Pediatric Myasthenia Gravis.

International ophthalmology clinics
2026

Case Report: Vitiligo and Alopecia Universalis Following Rituximab Therapy in a Patient with Myasthenia Gravis.

Clinical, cosmetic and investigational dermatology
2026

Case Report: Dual response to efgartigimod in myasthenia gravis and comorbid autoimmune disorders: a case series.

Frontiers in immunology
2026

From Limited Samples to Mechanistic Insights: Exploratory Identification and Functional Validation of a hsa_circ_0062400/hsa_circ_0002397-miR-338-3p-NRP1 Axis in Myasthenia Gravis.

Endocrine, metabolic &amp; immune disorders drug targets
2026

Bridging the gap between patient and physician perspectives on management of generalized myasthenia gravis: a Delphi consensus study.

Orphanet journal of rare diseases
2026

The Effect of Thymectomy on the Incidence of Extrathymic Cancers and Autoimmune Diseases in Patients With Non-Thymomatous Myasthenia Gravis.

Muscle &amp; nerve
2026

Burden of glucocorticoid use in commercially insured adults with generalized myasthenia gravis in the United States: A retrospective claims-based analysis.

Medicine
2026

Hsa_circ_0000313/miR-1224-3p/MKNK2 Axis Modulates CD4+ T Cells by Activating p38 MAPK Signaling in Myasthenia Gravis.

Mediators of inflammation
2026

Very Late-Onset Generalized Myasthenia Gravis Presenting With Worsening Frailty.

Cureus
2026

Neuro-immune interactions underlying autoimmune diseases: insights from brain imaging data.

Molecular brain
2026

Italian recommendations for the diagnosis and treatment of myasthenia gravis.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2026

Morvan syndrome in a patient with progressing metastatic thymoma and myasthenia gravis.

BMJ case reports
2026

Risk of New-Onset Myasthenia Gravis Following COVID-19 Infection and Vaccination: A Population-Based Case-Control Study.

European journal of neurology
2026

Minimal Symptom Expression in Generalized Myasthenia Gravis: A Valuable Patient-Centric Treatment Goal.

European journal of neurology
2026

Effectiveness and Safety of Eculizumab in Highly Active AChR+gMG and Its Therapeutic Response in Different Subtypes of gMG.

ImmunoTargets and therapy
2026

Letter regarding impact of corticosteroid use on comorbidities in patients with myasthenia gravis in the US National Veterans Affairs Health Network.

Journal of the neurological sciences
2026

Thymic epithelial tumors at the crossroads of immunity, autoimmunity, and immunotherapy.

Cancer immunology, immunotherapy : CII
2026

Sexual health in neuromuscular diseases: Neglected challenges revealed by a scoping review.

Journal of neuromuscular diseases
2026

Neurological immune-related adverse events of immune-checkpoint inhibitors: an updated review.

Presse medicale (Paris, France : 1983)
2026

SEC-based isolation of phosphatidylserine-liposomes from biological samples for preclinical studies.

Analytical and bioanalytical chemistry
2026

Double-Filtration Plasmapheresis Versus Efgartigimod for Generalized Myasthenia Gravis: Severity-Stratified Benefits in a Prospective Observational Multicenter Study.

CNS neuroscience &amp; therapeutics
2026

A high-throughput screening platform for acetylcholinesterase inhibitors using a genetically encoded acetylcholine fluorescent sensor.

Frontiers in bioengineering and biotechnology
2026

The Fiscal Consequences for the Canadian Government of Efgartigimod in the Treatment of Generalized Myasthenia Gravis.

Journal of health economics and outcomes research
2026

Comorbidities and Treatment Patterns in People With Myasthenia Gravis in Denmark, Finland and Sweden: A Population-Based Observational Study.

Muscle &amp; nerve
2026

Clinical and quality-of-life outcomes associated with efgartigimod in patients with generalized myasthenia gravis transitioning from intravenous immunoglobulin.

Clinical neurology and neurosurgery
2026

Co-occurrence of systemic lupus erythematosus and myasthenia gravis: Insights from a cross-sectional cohort.

Clinical neurology and neurosurgery
2026

When Central Tolerance Fails: Thymic Malignancies at the Intersection of Cancer Immunity and Autoimmunity.

Cancers
2026

Shared genetic and neuroimmune architecture links type 1 diabetes with neurocognitive traits.

Nature communications
2026

Association between obesity and subsequent risk of myasthenia gravis: a nationwide population-based cohort study.

Acta neurologica Belgica
2026

Estimating the minimal clinically important difference for the Myasthenia Gravis Quality of Life revised scale (MG-QOL15R).

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
2026

Who Can Safely Discontinue Treatment in Myasthenia Gravis? Insights From a Long-Term Real-World Study.

European journal of neurology
2026

A Decade of Surgical Management of Thymic Tumours in Western Australia.

ANZ journal of surgery
2026

Old Foundations in a New Era of Myasthenia Gravis Therapy.

Muscle &amp; nerve
2026

Analysis of adverse drug reactions associated with ravulizumab: a retrospective pharmacovigilance study utilizing the FAERS database.

Frontiers in immunology
2026

Neuro-ophthalmic presentation of leptomeningeal metastasis of thymoma: a case report.

Frontiers in neurology
2026

CAR T cell therapy in autoantibody-mediated neurological disorders: a promising strategy.

Journal of neuroinflammation
2026

Elucidating genetic backgrounds of myasthenia gravis in Japanese by genome-wide association studies and multi-omics analyses of thymoma.

Nature communications
2026

Myasthenic Crisis Unmasking Myocardial Infarction with Nonobstructive Coronary Arteries in a Patient with Undiagnosed Myasthenia Gravis.

The Journal of the Association of Physicians of India
2026

Indirect Comparison of Nipocalimab Versus Efgartigimod and Rozanolixizumab in the Treatment of Generalized Myasthenia Gravis.

Advances in therapy
2026

Juvenile Myasthenia Gravis: An Indian Perspective.

Neurology India
2026

Advantages of negative-pressure suction device compared to traditional chest closed drainage in the management of patients after mediastinal mass resection.

Journal of thoracic disease
2026

Concurrent Nivolumab-Induced Myocarditis and Myasthenia Gravis: A Case Report.

Case reports in oncological medicine
2026

Isolated dysphagia masking myasthenia gravis diagnosis.

Arquivos de neuro-psiquiatria
2025

[Clinical characteristics and genetic analysis of a patient with Kennedy disease with secondary infertility as the initial symptom].

Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
2026

Case Report: Positioning head tilt observed in six dogs with meningoencephalitis of unknown origin.

Frontiers in veterinary science
2026

Application of Droplet Digital PCR in Sputum Samples in Myasthenia Gravis Patients with Pneumonia.

Infection and drug resistance
2026

Late-Onset Ocular Myasthenia Gravis-Like Symptoms During Erenumab Therapy for Chronic Migraine: A Case Report.

Biologics : targets &amp; therapy
2026

Single-stage concomitant extended thymectomy for myasthenia gravis and enucleation of a left recurrent laryngeal nerve schwannoma via median sternotomy.

General thoracic and cardiovascular surgery cases
2026

Caring beyond the procedure: a qualitative study on thoracic surgery nurses' perspectives on chronic illness experiences of individuals with myasthenia gravis undergoing thymectomy.

BMJ open
2026

Quality and reliability of myasthenia gravis-related short videos on TikTok and Bilibili: A cross-sectional study.

Digital health
2026

Clinical and electrophysiological characteristics of myasthenia gravis patients with concomitant type 2 diabetes mellitus.

Frontiers in neurology
2026

Cholinergic Crisis Associated With Standard-Dose Pyridostigmine in a Hemodialysis Patient With Ocular Myasthenia Gravis and Marked Weight Loss.

Cureus
2026

Seizure as an Atypical Presentation of Myasthenia Gravis: A Rare but Critical Diagnostic Challenge.

Clinical case reports
2026

Astragaloside IV ameliorates experimental autoimmune myasthenia gravis through multi-target regulation of immune-microbiota-metabolism network and ferroptosis inhibition.

Pathology, research and practice
2026

Experience Using Efgartigimod to Treat Juvenile Myasthenia Gravis in China: A Multicenter Retrospective Study.

Muscle &amp; nerve
2026

Increased Prevalence of Extrathymic Neoplasms in Myasthenia Gravis Patients-A Population-Based, Matched Case-Control Study.

Muscle &amp; nerve
2026

Clinical and economic outcomes of therapeutic plasma exchange and intravenous immunoglobulin for treating adults with autoimmune neurological disorders: a systematic review and meta-analysis.

BMC neurology
2026

Cloudy or Clear? Readability and Content Analysis of Patient Education Materials in Myasthenia Gravis.

Muscle &amp; nerve
2026

Myasthenia gravis and pregnancy: a systematic review and meta-analysis.

Journal of neurology
2026

Efficacy and safety of telitacicept for myasthenia gravis in real-world practice and exploratory outcomes in the elderly subgroup.

Clinical immunology (Orlando, Fla.)
2026

Neoadjuvant BO-112 and hypofractionated radiation therapy with or without nivolumab in soft tissue sarcoma: preclinical and phase 1 results.

Cancer discovery
2026

[Diagnosis of myasthenia gravis in a patient with polymyositis].

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
2026

Physical and respiratory training in patients with myasthenia gravis: a systematic review with meta-analysis.

Scientific reports
2026

Early-Onset Immune Checkpoint Inhibitor-Induced Myasthenia Gravis Following First-Cycle Pembrolizumab: Diagnostic Challenges and Management Strategies.

Cureus
2026

Rapidly Progressive Overlap of Immune Checkpoint Inhibitor-Induced Myositis and Myasthenia Gravis: Diagnostic and Therapeutic Challenges.

Cureus
2026

Non-Motor Symptoms in Myasthenia Gravis Patients: Evaluation of Auditory and Olfactory Functions.

Noro psikiyatri arsivi
2026

Evaluation of Muscle Oxygenation by Functional Near-Infrared Spectroscopy in Patients with Myasthenia Gravis During Rest and Exercise.

Noro psikiyatri arsivi
2026

Elevated serum Interleukin-39 in Myasthenia gravis: a possible biomarker.

European journal of medical research
2026

Distinguishing pharmacological toxicity from disease severity and lifestyle confounders in myasthenia gravis comorbidity models.

Journal of the neurological sciences
2025

Giant cell myositis confined to the lower extremities without associated thymoma or myasthenia gravis: a case report.

Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology
2026

Efficacy and safety of immunosuppressants and immunomodulators in juvenile myasthenia gravis: a systematic review and meta-analysis.

Journal of translational medicine
2026

Zilucoplan is effective for ravulizumab-refractory generalized myasthenia gravis with the C5 p.Arg885His variant: a case report.

Neuromuscular disorders : NMD
2026

Robot-assisted versus video-assisted surgery for early functional recovery in patients with non-small-cell lung cancer: a systematic review and meta-analysis of propensity score-based matching studies.

Journal of robotic surgery
2026

Effective Use of the Thoracolumbar Interfascial Plane Block With Total IV Anesthesia for Laminoplasty in a Patient With Myasthenia Gravis: A Case Report.

Cureus
2026

Rapid Symptomatic Improvement and Long-Term Minimal Symptom Expression in a Myasthenia Gravis Patient Treated With Zilucoplan Without Maintenance Cholinesterase Inhibitors, Corticosteroids, or Immunosuppressants: A Case Report.

Cureus
2026

Emergency use of eculizumab in impending and manifest myasthenic crisis: a retrospective case series.

Therapeutic advances in neurological disorders
2026

Miglustat: a first-in-class enzyme stabilizer for cipaglucosidase alfa for the treatment of late-onset Pompe disease.

Therapeutic advances in rare disease
2026

The temporal sequence of myasthenia gravis and neuromyelitis optica spectrum disorder: a case report and systematic review of 74 patients.

Frontiers in neurology
2026

Real-World Evaluation of Efgartigimod in Generalized Myasthenia Gravis: A Single-Center Experience.

Journal of clinical neuromuscular disease
2026

A Novel Truncating Pathogenic Variant in RRM2B in a Kurdish Family With Autosomal-Dominant Chronic Progressive External Ophthalmoplegia Plus (PEOA5).

Journal of clinical neuromuscular disease
2026

Isolated bilateral facial palsy as the initial presenting manifestation of generalized myasthenia gravis preceding myasthenic crisis.

Neurologia
2026

Successful prehospital resuscitation of a young female patient with myasthenia gravis experiencing cardiopulmonary arrest due to complete airway obstruction: a case report and review of the literature.

Journal of medical case reports
2026

Triple M syndrome (myasthenia gravis, myocarditis and myositis) following atezolizumab in small cell lung carcinoma.

BMJ case reports
2026

Rethinking rituximab in neuroimmunology: Real-world efficacy, cost-effectiveness, and long-term remission.

Journal of neuroimmunology
2026

Progress in the Treatment of Refractory Myasthenia Gravis.

Revista de neurologia
2026

The Relationship Between Immune Semaphorins and Myasthenia Gravis.

Brain and behavior
2026

Early versus late add-on therapy in generalized myasthenia gravis: a multicenter real-world cohort study.

Journal of neurology
2026

Single-cell RNA-sequencing of myasthenia gravis reveals transcriptional heterogeneity and dysfunction of immune cell populations.

International immunology
2026

Association between vaccination and myasthenia gravis: a systematic review and meta-analysis.

Frontiers in immunology
2026

Adverse Childhood Experiences and Psychological Health in Patients with Myasthenia Gravis: A Study Incorporating an Online Positive Mental Health Learning Program.

Healthcare (Basel, Switzerland)
2026

Single-cell profiling of immune reset in patients with refractory generalized myasthenia gravis receiving autologous CD19/BCMA CAR-T cell therapy.

Med (New York, N.Y.)
2026

Current status and challenges of biologic targeted therapy for myasthenia gravis in China.

Intractable &amp; rare diseases research
2026

Case Report: Thymoma-associated myasthenia gravis, myositis, myocarditis, and anti-GAD65 autoimmune encephalitis: a unique case of paraneoplastic polyautoimmunity.

Frontiers in immunology
2026

Safety and Effectiveness of Eculizumab in Patients With Refractory Ocular or Ocular-Predominant Myasthenia Gravis: A Case Series.

Muscle &amp; nerve
2026

Immunotherapy Safety in Thymic Epithelial Tumors: Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System.

JMIR cancer
2026

Clinical course and prognosis of chronic autoimmune neuropathies requiring intensive care: a retrospective cohort study.

Journal of neurology
2026

A comprehensive electrooculography measurement system and protocols for screening myasthenia gravis.

MethodsX
2026

Telitacicept for refractory AChR-positive generalized myasthenia gravis: a retrospective real-world study.

Frontiers in immunology
2026

Outcomes of preoperative medical consultations for elective non cardiac surgical procedures at tertiary care center.

Pakistan journal of medical sciences
2026

Simultaneous Diagnosis of Myasthenia Gravis and Neurosyphilis, With Symptoms Improving After Neurosyphilis Treatment: A Case Report.

Cureus
2026

High expression of IRF8 in AChR-specific cells regulates the function of B cells.

Immunology letters
2026

Are you weary of illness? Coping and existential positioning in life with myasthenia gravis.

Medicine, health care, and philosophy
2026

Real-World Outcomes of Efgartigimod in Adult Myasthenia Gravis.

Cureus
2026

Differential response to ofatumumab in anti-AChR and anti-MuSK positive myasthenia gravis patients: a single-center retrospective study.

Therapeutic advances in neurological disorders
2026

Immune Dysregulation: Navigating Autoimmune Disorders in Exotic Companion Animals.

The veterinary clinics of North America. Exotic animal practice
2026

Current evidence and knowledge gaps in family planning and pregnancy in myasthenia gravis, NMOSD, and MOGAD.

The Lancet. Neurology
2026

Pregnancy and antibody-mediated diseases: evidence and gaps.

The Lancet. Neurology
2026

[A drooping gaze, a cold clue: Late-onset presentation of myasthenia gravis].

Revista espanola de geriatria y gerontologia
2026

Patient Perceptions of Needs and Expectations Regarding the Current Management of Myasthenia Gravis: A Biopsychosocial Study.

Neurology and therapy
2026

Myasthenia Gravis With Acetylcholine Receptor Antibodies in the Very Old: Treatment Challenges and Diagnostic Pitfalls.

European journal of neurology
2026

Combined adapted physical activity and art-therapy intervention in myasthenia gravis: Study protocol for a randomized crossover pilot trial.

Contemporary clinical trials
2026

Low Prevalence and Inconsistency of LRP4-IgG Detection in Suspected Myasthenia Gravis: A Multicenter CBA Comparison.

Neurology(R) neuroimmunology &amp; neuroinflammation
2026

Nationwide trends in mediastinal tumor and myasthenia gravis surgery in Japan: a decade claims-based analysis (2014-2023).

International journal of clinical oncology
2026

Outcomes following single-level lumbar fusion in patients with myasthenia gravis.

Journal of orthopaedics
2026

The role and mechanism of IL‑35 in myasthenia gravis (Review).

International journal of molecular medicine
2026

Assessment of Voice and Speech attributes in Adult Patients with Myasthenia Gravis. A case control study.

Folia phoniatrica et logopaedica : official organ of the International Association of Logopedics and Phoniatrics (IALP)
2026

Inflammatory biomarker panels in peripheral blood: association with myasthenia gravis onset and severity.

Frontiers in neurology
2026

Monocyte-macrophage SAMHD1 alleviates EAMG by modulating the cGAS-STING pathway.

Journal of neuroinflammation
2026

Qiangji Jianli Decoction attenuates skeletal muscle injury in rats with experimental autoimmune myasthenia gravis via the GRP78/IRE1α/GPX4 signaling pathway.

Journal of ethnopharmacology
2026

Clinical response to therapeutic plasma exchange in patients with immune-mediated inflammatory diseases of the central nervous system.

Anales de pediatria
2026

The Duke MG Patient Registry III. Comparative Effectiveness of Azathioprine and Mycophenolate Mofetil in Generalized Myasthenia Gravis, a Retrospective Single Center Review.

Muscle &amp; nerve
2025

First Paediatric Case of mRNA COVID-19 Vaccine Associated New Onset Systemic Myasthenic Crisis.

Sisli Etfal Hastanesi tip bulteni
2026

Clinical outcomes, serum IgG changes, and follow-up observations in the treatment of anti-AChR antibody-positive generalized myasthenia gravis with Efgartigimod.

BMC neurology
2026

Rapid efficacy of efgartigimod for generalized myasthenia gravis patients in acute exacerbations/worsening: multicenter real-world retrospective study.

Journal of neurology
2026

[Is it myasthenia gravis?].

MMW Fortschritte der Medizin
2026

Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB-IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 study.

The Lancet. Oncology
2026

Thymectomy with or without maintenance therapy for myasthenia gravis patients: a tri-center, real-world study.

Therapeutic advances in neurological disorders
2026

Case-Based Lessons on Remote Patient Monitoring in Neurology Using Consumer-Grade Wearables.

Journal of central nervous system disease
2026

Genetic insights into biological aging and myasthenia gravis: a Mendelian randomization study of telomere length, epigenetic clocks, and mitochondrial DNA copy number.

Clinical epigenetics
2026

Docosahexaenoic acid supplementation aggravates myasthenia gravis through immune dysregulation.

Journal of neuroimmunology
2026

Mendelian randomization followed by single-cell RNA sequencing exploration identifies effector memory CD4+ T cells as a risk factor for myasthenia gravis.

Medicine
2026

Factors Influencing the Conversion of Ocular Myasthenia Gravis to Generalized Myasthenia Gravis: A Retrospective Cohort Study.

Journal of ophthalmology
2026

C-Reactive Protein and Neurological Autoimmune Diseases: Bridging the Diagnostic and Pathogenic Gap.

International journal of molecular sciences
2026

Long-Term Response Without Immune-Related Adverse Events to Atezolizumab Treatment in TMB-High Thymoma: A Case Report from the KOSMOS-II Study.

Journal of clinical medicine
2026

Perceived Fatigue and Associated Psychological Factors in Patients with Myasthenia Gravis.

Healthcare (Basel, Switzerland)
2026

Associations between myasthenia Gravis and outcomes following cardiac surgery: an analysis of the nationwide inpatient sample.

BMC anesthesiology
2026

Takotsubo cardiomyopathy in myasthenia gravis: a systematic review of case reports with subtype-based analysis.

International journal of emergency medicine
2026

Postoperative hormonal modulation in a patient with granulosa cell tumor and myasthenia gravis: a gyneco-oncologic perspective.

Annals of medicine and surgery (2012)
2025

Telitacicept demonstrates high probability of efficacy in myasthenia gravis: a Bayesian real-world study.

Frontiers in neurology
2026

Immuno-deficient features of thymoma-associated myasthenia gravis patients with hypogammaglobulinemia: A condition comparable to Good's syndrome.

Journal of neuroimmunology
2026

Associated Autoimmunity in Myasthenia Gravis in Denmark: A Nationwide Case-Control Study.

European journal of neurology
2026

Diphtheria Presenting With Cranial Neuropathy: The Patch Unseen.

Cureus
2026

The Differential Diagnosis of Diplopia.

Deutsches Arzteblatt international
2026

Application analysis of transfected cell method for detecting AChR antibodies in MG patients.

Scientific reports
2026

Acute Myasthenic-Like Illness: A Common Presentation of Neurotoxic Snakebite in a Tropical Region.

The American journal of tropical medicine and hygiene
2026

Immune Checkpoint Inhibitor-Related Myositis and Associated Triad Overlap Syndrome.

Arthritis care &amp; research
2026

Diagnostic performance and safety of the edrophonium test in myasthenia gravis: a retrospective case-control study.

Neurological research and practice
2026

Comparative outcomes of robotic- and video-assisted thoracoscopic surgery in thymectomy: a systematic review of implications for myasthenia gravis remission and long-term oncology.

Journal of thoracic disease
2026

AI-driven biomarker learning for the early diagnosis of neurodegenerative diseases: ABLEDx.

Journal of nanobiotechnology
2026

Lymphocyte alterations and elevated complement signaling are key features of refractory myasthenia gravis.

Med (New York, N.Y.)
2026

Longitudinal MuSK antibody levels may correlate with disease severity in MuSK myasthenia gravis.

Journal of neuroimmunology
2026

Letter to editor: Early real-life experience on zilucoplan for generalized myasthenia gravis: ZILU25 multicenter observational study.

Journal of the neurological sciences
2026

Real-world use of efgartigimod in acetylcholine receptor antibody-positive generalized myasthenia gravis: experience from two centers in Greece and Cyprus.

Frontiers in neurology
2026

Myasthenia gravis following the initiation of statin therapy: A multinational self-controlled case series study.

Journal of internal medicine
2026

Fusion of deep learning and radiomics with dynamic spatiotemporal modeling for non-small cell lung cancer recurrence risk assessment after microwave ablation.

BMC medical imaging
2026

Incidence and clinical characteristics of concurrent thyroid eye disease and ocular myasthenia gravis.

Canadian journal of ophthalmology. Journal canadien d'ophtalmologie
2026

Global Research Landscape in T Cells and Myasthenia Gravis: Trends, Collaborations, and Future Directions.

Molecular neurobiology
2026

Multisystemic Malakoplakia Revealed by 18F-FDG PET/CT: A Case of Concomitant Bilateral Osteomyelitis and Genitourinary Involvement.

Clinical nuclear medicine
2026

Incidental finding of "H"-type duplex gallbladder: a case report.

Journal of medical case reports
2026

Evaluation of neuromuscular blocker use in myasthenia gravis patients undergoing rapid sequence intubation.

The American journal of emergency medicine
2026

Neurologists' decision-making in the management of generalised myasthenia gravis: Therapeutic inertia and treatment choices.

Journal of neuromuscular diseases
2026

Delayed recovery following myasthenic exacerbation and subsequent endplate-protecting treatment.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2026

Frequent co-occurrence of AChR-positive myasthenia gravis in facioscapulohumeral muscular dystrophy suggests a novel disease association.

Journal of neurology, neurosurgery, and psychiatry
2026

Improved Neuromuscular Transmission Following Thymectomy in Juvenile Myasthenia Gravis: A Case Series.

Muscle &amp; nerve
2026

Successful use of immune checkpoint Inhibition in a patient with myasthenia gravis and recurrent endometrial cancer- expanding access beyond initial clinical trial eligibility.

Gynecologic oncology reports
2026

Safety of home administration of cipaglucosidase alfa plus miglustat in late-onset Pompe disease: results from multiple clinical trials.

Therapeutic advances in rare disease
2026

Electrodiagnostic Approach to Defects of Neuromuscular Transmission.

Muscle &amp; nerve
2026

[Myasthenic syndromes: retrospective analysis of two patient cohorts].

Fortschritte der Neurologie-Psychiatrie
2026

Rozanolixizumab-induced aseptic meningitis in AChR-thymoma associated myasthenia gravis.

Acta neurologica Belgica
2026

Corticosteroid-Refractory Juvenile Myasthenia Gravis: Treatment Responses and Prognosis in a Large Chinese Cohort.

Muscle &amp; nerve
2026

Clinical characteristics and treatment outcomes in thymoma- related aplastic anemia: a case report and literature review.

Journal of cardiothoracic surgery
2026

Serum from patients with acetylcholine receptor antibody-positive myasthenia gravis triggers pathogenic changes in human myotube cells.

Journal of neuroimmunology
2026

Low-dose IL-2 Ameliorates Experimental Autoimmune Myasthenia Gravis in Rats by Restoring the CD4-positive Helper T-cell Balance Via the JAK/STAT5 Pathway.

Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology
2026

Iatrogenic botulism: a risk for botulinum toxin's medical use?

Journal of neural transmission (Vienna, Austria : 1996)
2026

Fc receptor-like proteins and their role in B-cell responses and autoimmune diseases.

Immunology letters
2026

Multi-omics profiling reveals intrathymic triggers and novel biomarkers in thymoma-associated myasthenia gravis.

Biomarker research
2026

Efgartigimod for steroid-resistant autoimmune glial fibrillary acidic protein astrocytopathy: a case report and literature review.

Journal of neuroimmunology
2025

ENGAGE: Analyzing the value of virtual reality in a patient-centric immersive learning program in myasthenia gravis for healthcare professionals.

Frontiers in neurology
2026

Azathioprine Toxicity in Patients With Myasthenia Gravis: A Single Center Experience.

Muscle &amp; nerve
2025

Exploring the impact of age of onset on stereoacuity in patients with myasthenia gravis.

Frontiers in ophthalmology
2025

The rare report of unicentric Castleman disease with concurrent myasthenia gravis and paraneoplastic pemphigus: a case report with a focused review of the literature.

Frontiers in oncology
2026

Fracture Occurrence Within FRAX-Defined High-Risk Myasthenia Gravis: An Exploratory Stratification by Age and Activities of Daily Living.

Journal of clinical medicine
2026

A Shift from Standard Median Sternotomy to Robotic-Assisted Thoracic Surgery for Resection of Anterior Mediastinal Tumors.

Journal of clinical medicine
2026

Gut Microbiota as Neuroimmune Modulators in Myasthenia Gravis: Mechanistic Insights from the Gut-Brain Axis to Therapeutic Innovations.

The American journal of Chinese medicine
2026

Assessing the Value Contribution of Vyvgart® (Efgartigimod Alfa) in the Treatment of Generalized Myasthenia Gravis with Acetylcholine Receptor Antibody in Spain Through Multi-criteria Decision Analysis.

Advances in therapy
2026

1-Year Clinical Outcome Post-Myasthenic Crisis: A Multicenter Prospective Study in China.

European journal of neurology
2026

Aberrant expression of triggering receptor expressed on myeloid cell-1 is involved in the immunopathological mechanism of myasthenia gravis.

Autoimmunity
2025

Add-on efgartigimod in myasthenic crisis: a promising treatment option.

Frontiers in neurology
2025

Efgartigimod combined with rituximab helps improve the symptoms and reduce the use of corticosteroids in patients with MuSK antibody-positive MG: a single case report.

Frontiers in immunology
2026

Exploring Pembrolizumab-Induced IM3OS in a Patient With Bladder Cancer.

Pharmacology research &amp; perspectives
Ver todos os 13.933 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Fundada em 1984 como Associação dos Miastênicos do Brasil.

Doença com base genética

Um médico geneticista pode ajudar no diagnóstico de Miastenia gravis e no aconselhamento genético da família.

Vai consultar um especialista? Confirme o registro dele no conselho.
Conselhos e sociedades

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Ordenadas pelo número de sintomas em comum.

Perguntas frequentes

O que as famílias mais perguntam sobre esta doença — cada resposta com a fonte de onde saiu

Protocolo oficial do Ministério da SaúdePCDT: Miastenia Gravis

Este é o documento que organiza diagnóstico, tratamento e dispensação de Miastenia gravis no SUS. O que a farmácia entrega é o que está no PCDT vigente — não o que foi aprovado fora do Brasil.

Respostas geradas por IA a partir das fontes citadas

É uma doença rara e autoimune da junção neuromuscular que provoca fraqueza cansativa nos músculos do corpo. Ela afeta pessoas de qualquer idade, desde a infância até a fase adulta.

Referências

Fontes citadas no texto, publicações do grafo e bases de dados usadas neste verbete

10 publicações do grafo RarasNet (PubMed) · 8 bases de dados. Títulos, periódicos e PMIDs vêm direto da fonte, sem intermediação de IA.

  1. ORPHA:589
    Orphanet
  2. GARD:7122
    GARD (NIH)
  3. Q8285
    Wikidata

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Citar este verbete

Raras. (s.d.). Miastenia gravis. Em Raras — Enciclopédia de Doenças Raras do Brasil. https://raras.org/doenca/miastenia-gravis

Formato APA. Conteúdo sob CC BY 4.0 — reuso livre com atribuição.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Compêndio · Raras BR

Miastenia gravis

ORPHA:589 · MONDO:0009688
🇧🇷 Brasil SUS
CEAF
1BPiridostigmina1BAzatioprina1AEculizumabe
SIGTAP
2 procedimentos
Geral
Prevalência
1-9 / 100 000
Herança
Multigenic/multifactorial, Not applicable
CID-10
G70.0 · Miastenia gravis
CID-11
Ensaios
153 ativos
Início
All ages
Prevalência
20.0 (Europe)
MedGen
UMLS
C0751340
Repurposing
4 candidatos
ambenonium — cholinesterase inhibitor
edrophonium — acetylcholinesterase inhibitor
mestinon
+1 outros
Wikidata
Wikipedia
Papers 10a

📋 Origem dos dados

Esta página agrega dados de fontes públicas e oficiais. Dados sobre cobertura no SUS (PCDT, CEAF) são verificados ativamente por agente proativo (ver badge no infobox). Demais dados têm atribuição de fonte + data da última sincronização — clique para abrir o original.

Doença rara (ontologia)
fonte: Orphanet
Identificador unificado
fonte: MONDO
Genética mendeliana
fonte: OMIM
Indexação biomédica
fonte: MeSH (NLM)
Dado público estruturado
fonte: Wikidata
Medicamentos aprovados FDA
fonte: FDA OpenFDA
Rara